RHYTHM PHARMACEUTICALS, INC. (RYTM) Net Income (Loss) Attributable to Parent USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Rhythm Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Rhythm Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$141 M, a 171% decline year-over-year.
  • Rhythm Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$274 M, a 51.7% decline year-over-year.
  • Rhythm Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$185 M, a 1.97% decline from 2022.
  • Rhythm Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$181 M, a 160% decline from 2021.
  • Rhythm Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$69.6 M, a 48% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$274 M -$141 M -$89.2 M -171% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$185 M -$41.6 M +$860 K +2.02% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$186 M -$44.2 M -$3.3 M -8.08% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$182 M -$46.7 M -$1.7 M -3.78% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-08
Q1 2023 -$181 M -$52.2 M +$585 K +1.11% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$181 M -$42.5 M +$373 K +0.87% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$181 M -$40.9 M -$5.75 M -16.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$176 M -$45 M -$9.61 M -27.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$166 M -$52.8 M -$96.5 M -221% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$69.6 M -$42.9 M -$7.97 M -22.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$61.6 M -$35.1 M -$1.29 M -3.81% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$60.4 M -$35.4 M -$4.27 M -13.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$56.1 M $43.8 M +$77.9 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$134 M -$34.9 M -$1.94 M -5.89% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$132 M -$33.8 M +$2.19 M +6.07% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$134 M -$31.1 M +$11.7 M +27.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-02
Q1 2020 -$146 M -$34.2 M -$5.19 M -17.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-02
Q4 2019 -$141 M -$33 M -$7.45 M -29.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$133 M -$36 M -$18.3 M -104% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 -$115 M -$42.8 M -$28.4 M -197% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
Q1 2019 -$86.6 M -$29 M -$12.5 M -76% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 -$74.1 M -$25.5 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$17.7 M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$14.4 M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$16.5 M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.